An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Authors :: Eric Angevin
Jonathan H. Goldman
Karen Kelly
Everett E. Vokes
Todd M. Bauer
Apurvasena Parikh
John H. Strickler
Monica Motwani
T. Yi
Daniel Morgensztern
Rebecca S. Heist
J. Wu
R. Camidge
Minal A. Barve
Source :: Annals of Oncology. 29:viii496-viii497
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
business.industry
non-small cell lung cancer (NSCLC)
Hematology
medicine.disease
Phase i study
Internal medicine
medicine
Erlotinib
Open label
business
medicine.drug

Tools